Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

Meeting the needs of the community is one of North Idaho College President Nick Swayne’s main goals. So when he saw a growing trend toward classical education in the Inland Northwest with charter, ...

Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...